Close Icon

AI and the Future of Pharmacovigilance

Today’s data explosion is forcing pharmacovigilance professionals to use artificial intelligence technologies to get answers in a more proactive way. “Just putting 100 more people in a room and trying to look at documents and bounce ideas off of each other’s head isn’t going to work anymore,” says Bruce Donzanti, former Senior Group Director, Global Regulatory Pharmacovigilance Innovation Policy at Genentech.

Donzanti joins the podcast for a lively discussion about the evolution of pharmacovigilance and how pharma companies and health authorities are working together to advance the future of safety science.

In this episode of Safety Signals, we discuss:

– How AI has become a necessity, not just a nice-to-have

– How human biases have plagued the industry for decades

– The quest for rapid access to quality data

* The views of the hosts and guests featured on Safety Signals are their own and do not necessarily reflect the views of Saama or the individual companies for which the guests may work.

About Saama Safety Signals

Introducing Safety Signals, the show for pharmacovigilance professionals, benefit risk managers, epidemiologists, and other patient safety stakeholders. From pharma leaders to academics and scientists, we provide expert perspectives on the challenges, opportunities, and technologies that are shaping the future of the safety sciences. Get ready to be inspired and energized as you work to reduce the risk of life-changing–and life SAVING–medical treatments.

Listen & Subscribe
Solutions

Active Safety Analytics for Pharma (ASAP)

Operations Insights

Meet Your Hosts & Guests

Benzi Mathew

Benzi
Mathew

Vice President & Partner
Saama Technologies

Linkedin-in Twitter Envelope
Ramprasad Keshavamurthy

Ramprasad
Keshavamurthy

Senior Director
Saama Technologies

Linkedin-in Envelope

Bruce Donzanti

Bruce Donzanti

Bruce Donzanti

Former Senior Group Director, Global Regulatory Pharmacovigilance Innovation Policy at Genentech

Bruce Donzanti

Bruce
Donzanti

Former Senior Group Director, Global Regulatory Pharmacovigilance Innovation Policy
Genentech

Linkedin-in

Terms & Conditions

By inquiring about Saama’s Database Lock in a Day, you agree to be contacted by Saama and to allow Saama to use, maintain, store, and protect your personal data in accordance with our Privacy Policy.

Eligibility details are for informational purposes only. Saama, in its sole discretion, will determine your eligibility based on the information you disclose as part of the intake process. If Saama determines that you are eligible to participate, you will be notified by separate email. Eligibility depends on certain criteria, such as the size of your company, the types of clinical trials you sponsor, and the number of patients in–and stages of–your current clinical trials.

By completing the request form, you represent that you have authority to proceed on behalf of your company. Should you agree to participate, you agree to reasonably cooperate with Saama in following the guidelines and procedures required for integrating, standardizing, and analyzing your data. Participation requires the use of our Smart Data Quality application, a technology-agnostic AI engine that sits on top of your current infrastructure. The application can be used immediately, and you’re only charged for the services you use based on a predetermined estimate.

Information you share with Saama during your participation may be anonymized and/or aggregated, and made available publicly in Saama marketing materials. This information may include: types of systems and processes involved, types of departments involved, and size and regional location of your company. Such information will never be directly associated with you, nor will you or your company be identifiable without express written permission.